Intuitive Surgical (ISRG) After Board Appointment The Undervalued Narrative Still Stands
Intuitive Surgical (ISRG) announced new boardroom developments on 2 November 2026, appointing Humana executive Aaron Martin as director. His term is set to begin on 1 January 2027.
At a share price of US$443.59, Intuitive Surgical has seen short term momentum pick up, with a 30 day share price return of 5.56% and a 90 day gain of 12.44%. This comes even though the year to date share price return is down 21.07% and the 1 year total shareholder return is down 19.28%, while the 3 year total shareholder return of 45.31% and 5 year total shareholder return of 27.23% point to a stronger longer term story.
Scan how Intuitive Surgical fits into the broader medical technology story by comparing it with hand picked 86 robotics and automation stocks across the market.
After a sharp bounce, but with Intuitive Surgical still trading below both analyst targets and an internal fair value estimate, the gap between market price and implied worth has widened. How far apart are those two views really?
Most Popular Narrative: 30% Undervalued
On the latest available view, the narrative fair value for Intuitive Surgical sits at $630.48 compared with the last close at $443.59. This sets up a wide valuation gap that the narrative tries to explain. According to pbco, an investor in the Simply Wall St Community who wrote the narrative, the core of that gap comes from how the business model and patent position shape recurring revenue.
I would like to point out that ISRG uses the Razor Blade Business Model. According to FactSet Data Systems as of 12/31/2025, 59.8% of their revenue comes from Instruments and accessories, 24.58% from Systems, and 15.62% from services. Once a system is sold it generates a recurring revenue stream for its working life. This is similar to a razor company that can afford to give you a deal for buying the razor and make its profit from selling you the replacement razor blades.
See why 9 investors see Intuitive Surgical as 30% undervalued.
Result: Fair Value of $630.48 (UNDERVALUED)
Still, the Intuitive Surgical narrative depends on patents holding their edge and on legal disputes around third party repairs not reshaping the economics of its instruments business.
Find out about the key risks to this Intuitive Surgical narrative.
Another View: What The Market Multiple Says About Intuitive Surgical
While the Intuitive Surgical community narrative leans on a $630.48 fair value, the current market is attaching a very different label. The stock trades on a P/E of 52x, compared with 28.8x for peers and 25.3x for the wider US Medical Equipment group, and a fair ratio of 37.9x suggests a level the market could eventually lean toward. That wide gap points to valuation risk if sentiment cools, so the question becomes whether you think earnings quality and patent strength are enough to hold that premium.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
The debate over Intuitive Surgical's value is already sharp, so consider this a starting point and review the numbers yourself today. To explore the potential upsides our work highlights, take a closer look at the 3 key rewards.
Looking for more investment ideas beyond Intuitive Surgical?
Do not stop with Intuitive Surgical. Broaden your watchlist now, compare different setups, and keep fresh ideas coming so you are not relying on a single story.
- Target potential mispricing by scanning companies that combine quality metrics with attractive valuations through the 32 high quality undervalued stocks.
- Strengthen your focus on resilience by checking a list of solid balance sheet and fundamentals (24 results) that can better withstand tough conditions and funding shocks.
- Get ahead of the crowd by searching a pool of 20 high quality undiscovered gems before wider attention closes the gap in expectations.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com